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Abstract 
 
Background.  
Lung cancer outcomes in the UK are worse than in many other developed nations. Symptom awareness 
campaigns aim to diagnose patients at an earlier stage to improve cancer outcomes.  
 
Methods.  
An early diagnosis campaign for lung cancer commenced in Leeds, UK in 2011 comprising public and 
primary-care facing components. Rates of community-referral for chest X-ray, and lung cancer stage 
(TNM seventh edition) at presentation were collected from 2008 to 2015. Linear trends were assessed 
by 2 test for trend in proportions. Headline figures are presented for the three years pre-campaign 
(2008-2010) and the three most recent years for which data is available during the campaign (2013-
2015).  
 
Findings.  
Community-ordered chest X-ray rates per year increased from 18,909 in 2008-2010 to 34,194 in 2013-
2015 (80.8% increase). A significant stage shift towards earlier stage lung cancer was seen (χ2(1)=32·2, 
p<0·0001). There was an 8·8 percentage point increase in the proportion of patients diagnosed with 
stage I/II lung cancer (26·5% pre-campaign vs. 35·3% during campaign) and a 9·3% reduction in the 
absolute number of patients diagnosed with stage III/IV disease (1,254 pre-campaign vs. 1,137 during 
campaign).  
 
Interpretation.  
This is the largest described lung cancer stage-shift in association with a symptom awareness campaign. 
A causal link between the campaign and stage-shift cannot be proven but appears plausible. Limitations 
of the analysis include a lack of contemporary control population.  
 
Funding. 
UK National Awareness and Early Diagnosis Initiative, Leeds Primary Care Trust, Leeds Clinical 
Commissioning Groups, Leeds City Council.  
 
Word count = 243 
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Key messages 
 
What is the key question? 
Can symptom awareness campaigns for lung cancer lead to meaningful improvements in lung cancer 
outcomes?  
 
What is the bottom line? 
A large and sustained increase in community ordered chest X-rays and significant stage-shift in lung 
cancer have been observed alongside a prolonged symptom awareness campaign; a causal link cannot 
be proven but appears plausible.  
 
Why read on? 
This is the largest stage-shift in lung cancer to be described outside a screening trial, and suggests 
benefit to continued symptom awareness campaigns as one strategy to improve lung cancer 
outcomes.  
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Introduction 
 
A series of international comparisons have consistently demonstrated worse outcomes for patients 
diagnosed with lung cancer in the UK compared with other developed nations. 1-4 The International 
Cancer Benchmarking Partnership showed an adverse stage distribution in the UK compared with 
elsewhere, suggesting that delayed diagnosis may contribute to these poorer outcomes.5 In 2008, the 
UK Government and Cancer Research UK launched the National Awareness and Early Diagnosis 
Initiative (NAEDI) with the aim of achieving earlier cancer diagnosis to improve outcomes.6 A number 
of regional initiatives were funded and in 2012-2013 nationwide advertising campaigns sought to raise 
public awareness of early symptoms of common cancers, with the aim of increasing diagnosis of early 
stage cancers, and reducing the proportion of patients diagnosed following emergency presentation 
(known to be associated with poor outcomes).7,8 This study assessed lung cancer outcomes following a 
coordinated public awareness campaign and primary care educational programme in Leeds, UK 
originally funded by NAEDI. The primary outcomes of the campaign were the number of community-
ordered chest X-rays (CXRs) performed and the stage distribution of lung cancer cases. Secondary end-
points included route to diagnosis (including proportion diagnosed following emergency presentation), 
performance status, cancer treatment rates, and lung cancer survival and mortality.  
 
Methods 
 
This was a time-trend study, reviewing outcomes for patients diagnosed with lung cancer first seen at 
Leeds Teaching Hospitals (LTH) for the three years prior to initiation of the campaign (2008-2010), 
and for the five years over which the campaign has run for which data is available (2011-2015). The 
early diagnosis campaign comprising the four elements described below commenced in January 2011 
and has continued in various forms to date.  
 
First, a primary care health professional educational package highlighting the UK National Institute for 
Health and Clinical Excellence criteria for CXR referral (Clinical Guideline 24, 2005)9 and the 
importance of early lung cancer detection was delivered to general practitioners (GPs), community 
nurses/matrons, and community pharmacists in Leeds (21 presentations between 2011 and 2014). 
Second, a marketing communications campaign was developed including advertisements on buses and 
bus shelters, a targeted leaflet drop to 80,000 households, branded beer mats at pubs and working men’s 
clubs, branded pharmacy bags, and radio advertisements. The campaign initially targeted areas of high 
deprivation and lung cancer incidence in Inner East and Inner South Leeds, but subsequent 
communications were widened to include the whole city. The strapline for the campaign was “Got a 
cough? Get a check”, with subsequent advice stating “If you have a cough, breathlessness or chest pain 
for over three weeks, you need a chest x-ray to rule out serious lung problems”. Third, a team of 
community health educators delivered key messages to local target populations including recognition 
of respiratory symptoms, understanding that early diagnosis can lead to better outcomes, and 
highlighting ways of accessing CXRs. Finally, a self-request CXR service was established for patients 
aged 50 years and over with respiratory symptoms lasting 3 weeks or longer who had not had a CXR 
within the last three months. The referring clinician was the respiratory physician who produced the 
criteria; radiographers checked patients’ eligibility against these criteria and performed a posterior-
anterior CXR if appropriate. Patients were referred back to their GP or recalled for further investigation 
with CT scan if required.  
 
The number of community-ordered CXRs in Leeds (both GP-requested and self-requested CXRs) was 
extracted from the LTH radiology database. Outcome data for patients first seen at LTH with a new 
diagnosis of lung cancer between January 2008 and December 2015 were collected from both National 
Lung Cancer Audit (NLCA) submissions and the National Cancer Registration and Analysis Service 
(NCRAS) at Public Health England. Electronic records for cases identified by NCRAS which had not 
been included in LTH NLCA cohort were individually reviewed to check that they represented lung 
cancer first seen at LTH. Cases were excluded from analysis if there was definite pathological evidence 
of an alternative (non-lung) cancer primary site, lung cancer was thought unlikely following discussion 
at a cancer multi-disciplinary team (MDT) meeting, or if the patient was first seen at a peripheral 
hospital and referred to LTH for treatment. To avoid bias, cases where there was no information about 
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a cancer diagnosis available, or where the lung cancer diagnosis was questionable but the case had not 
been discussed at a cancer MDT remained in the cohort for analysis. Since 2015, both NLCA and 
NCRAS have derived data from a single national cancer dataset, the Cancer Outcome and Service 
Dataset (COSD). This is now the national standard for reporting all cancer activity in the National 
Health Service in England, with the result that the NLCA and NCRAS datasets should now be 
identical.10 
 
The following information was recorded: sex; age; index of multiple deprivation (derived from 
postcode); WHO performance status; TNM stage; pathological subtype; route to diagnosis; treatment; 
date first seen; diagnosis date; date of death or censor. Cases were grouped by year according to date of 
diagnosis. All cases diagnosed in 2008 and 2009 were restaged according to the TNM seventh edition 
to allow comparison of stage distribution over the course of the campaign. For synchronous lung 
cancers, the stage of the most advanced cancer was recorded. Patients with a second metachronous lung 
cancer diagnosed during the study period (following MDT review) were counted twice in the analysis. 
Routes to diagnosis were manually extracted for all cases and categorised as emergency presentation, 
respiratory clinic referral, intrahospital referral (referral from other specialties within LTH where the 
lung cancer diagnosis was considered incidental to presenting episode) or other (mostly radiological 
follow-up of pneumonia or pulmonary nodules). Treatments were classified as surgical resection, 
radical oncology (conventionally fractionated radical radiotherapy, stereotactic ablative body 
radiotherapy (SABR) or concurrent chemoradiation), palliative oncology (palliative chemotherapy, 
palliative radiotherapy, or a combination of both) or best supportive care. Lung cancer mortality data 
were obtained from the Office for National Statistics. The numbers of deaths and age standardised 
mortality rates (with 95% CIs) where the underlying cause was lung cancer (ICD-10 C33-C34) were 
provided for England and Wales, and Leeds from 2008 until 2016. Figures for Leeds are based on the 
boundaries of three Leeds Clinical Commissioning Groups as of May 2017. Figures are based on deaths 
registered rather than deaths occurring in each calendar year, and age standardised rates per 100,000 
population were standardised to the 2013 European Standard Population.  
 
Changes over the eight calendar years in patient characteristics, tumour characteristics, referral 
pathway, treatment, and 1-year survival were assessed by a one degree of freedom (df) 2 test for rend 
in proportions. Missing value (unknown) categories were not included in these tests. For pathological 
subtype, referral pathway and treatment, where the categories are not an ordered sequence, several 1df 
tests were calculated, each test comparing one specific category with the aggregate of the other specified 
categories. For treatment, the test compared radical treatment (surgical resection or radical oncological 
treatment) versus the other categories. Baseline data were collected over a 3-year period prior to 
initiation of the campaign (2008-2010). Headline figures are compared with the most recent three year 
period for which data are available (2013-2015, termed established campaign).  
 
The study was registered with the UK Clinical Research Network Study Portfolio (UKCRN ID 9447) 
and received ethics committee approval (MREC No 10/H1302/81).  
 
Role of the funding source 
 
The campaign was funded by NAEDI (UK Department of Health; co-chaired by Cancer Research UK) 
2011, NHS Leeds Primary Care Trust (2011-2013), the three Leeds Clinical Commissioning Groups 
(2013-current) and Leeds City Council (2013-current). NAEDI, the UK Department of Health, Cancer 
Research UK and Leeds City Council had no role in study design, data collection, interpretation, 
analysis, nor in the writing and submitting process. Co-authors employed by the Primary Care Trust 
and Clinical Commissioning Groups were members of the early diagnosis campaign team, and have 
been involved in study design, interpretation of data, report writing and the decision to submit for 
publication.  
 
Results 
 
Annual community referrals for CXR (subdivided between GP and self-request routes) are shown in 
Table 1. There was an 80·8% increase in annual referrals comparing pre-campaign with the period 
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during the established campaign (18,909 in 2008-2010 vs 34,194 in 2013-2015). Monthly community 
referrals for CXR are shown in Figure 1. Peaks in CXR requests were seen following GP educational 
events (January 2011, September 2011, November 2013), and following the national TV advertising 
campaign which ran in April-May 2012.  
 
A total of 5,800 lung cancer cases were identified from NLCA and NCRAS with diagnosis dates 
between January 2008 and December 2015, and a flow chart is shown in Figure 2. Cases excluded from 
analysis were as follows: 323 cases with pathological confirmation of alternative cancer; 20 cases 
thought unlikely to be cancer following discussion at a cancer MDT; and 698 cases listed as first seen 
at LTH but referred from peripheral centres. There were 15 cases with no information relating to a 
cancer diagnosis on our electronic record, and 31 cases where lung cancer was thought questionable but 
which had not been discussed at a cancer MDT. These 46 cases were included for analysis (data 
recorded as unknown where appropriate). A total of 58 metachronous primary lung cancers were 
diagnosed during the study period. The total number of lung cancer cases in the cohort for analysis was 
4,759. 
 
Demographic details and performance status of patients diagnosed with lung cancer at LTH are shown 
in Table 2. There were 577 diagnoses per year pre-campaign (2008-2010) and 590 per year during the 
established campaign (2013-2015). A peak in diagnoses occurred during the transition period in 2012 
when 649 diagnoses were made - a 12·5% increase in the number of cases. There were no significant 
trends in sex distribution, age, or performance status over the study period. There was a reduction in 
the proportion of patients from the most deprived quintile and a corresponding increase in patients from 
the least deprived quintile over the course of the study (χ2(1)=9·6; p=0·002).  
 
Stage distribution is shown in Table 3, and demonstrates a stage-shift towards earlier stage disease 
during the campaign (χ2(1)=32·2; p<0·0001). There was an 8·8 percentage point increase in the 
proportion of patients diagnosed with stage I/II disease (from 26.5% in 2008-2010 to 35.3% in 2013-
2015) and a corresponding 8.2 percentage point decrease in the proportion of patients diagnosed with 
stage III/IV disease (from 72·4% in 2008-2010 to 64·2% in 2013-2015). Furthermore there was a 9·3% 
reduction in the absolute number of patients diagnosed with stage III/IV disease comparing periods pre-
campaign and during the established campaign (1,254 in 2008-2010 vs 1,137 in 2013-2015). A change 
in pathological subtype was also observed, mainly related to a reduction in the proportion of cases 
classified as non-small cell lung cancer not otherwise specified (NSCLC NOS) (p<0·0001). A smaller 
reduction was observed in the proportion of patients without pathological confirmation of lung cancer, 
again reflecting national trends. This may have contributed to corresponding increases in the proportion 
of other groups.  
 
Route to diagnosis and treatment data are shown in Table 4. There were significant reductions in the 
proportion of patients diagnosed following emergency presentation and by intrahospital referral, with 
corresponding increases in the proportion diagnosed following clinic referral and by other routes such 
as pulmonary nodule follow-up (p<0·0001 for all linear trends). Comparing the pre-campaign period 
with the period during the established campaign, there was a 7·2 percentage point reduction in 
emergency presentation (from 36·0% to 28·8% respectively). The proportion of patients receiving 
radical therapy for lung cancer (surgery and radical oncology treatments combined) increased during 
the campaign (χ2(1)=60·6; p<0·0001). There was a reciprocal fall in the proportion of patients who 
received best supportive care. The trend to increased radical oncology treatments was apparent prior to 
the campaign starting, and largely reflects the increased use of SABR and concurrent chemoradiation 
(data not shown).  
 
One year survival increased during the campaign from 31·8% for 2008-2010 to 40·3% in 2013-2015 
(χ2(1)=26·0; p<0·0001 - Table 5). Table 6 and Figure 3 show mortality data for lung cancer in Leeds 
and England and Wales (total deaths and age-standardised mortality rates) between 2008 and 2016 (the 
last year for which data are available).11 Age-standardised mortality rates for lung cancer decreased in 
Leeds as well as in England and Wales over this period. The decrease over time was stronger in Leeds 
than in England and Wales both in absolute terms (17·7 vs. 7·5 per 100,000 respectively) and in relative 
terms (rate ratio 2016/2008: 0·81 vs. 0·88 respectively).  
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Discussion 
 
The primary end points of this study were the number of community-ordered CXRs and the stage 
distribution of lung cancers first seen at LTH. The interventions comprising the lung cancer campaign 
had a large, sustained effect on community CXR referrals, with an 80·8% increase comparing the pre-
campaign period and the period during the established campaign. The campaign comprised 
interventions targeting the public and health professionals, and coincided with a nationwide media 
campaign (Be Clear on Cancer) during 2012 and 2013. It is therefore impossible to attribute the rise in 
CXR referrals to any specific component of the local campaign and similarly we are unable to 
discriminate between the effects of the local and national interventions as they ran over the same time 
period. Nevertheless, three rounds of GP education events were each followed by surges in CXR 
referrals suggesting that an alteration in the threshold for CXR referral by GPs may have made an 
important contribution to the overall increase. Analysis of GP attendance data over this period would 
allow an opportunity to discriminate between changes in GP and patient behaviour. This is an area for 
future research, but these data were not available for the analysis presented here. This increase in CXR 
referrals coincided with a stage-shift of lung cancer presentation to a more favourable stage distribution. 
Due to the nature of the study, it is not possible to prove a causal link between the increase in CXR 
referrals and stage-shift. However, a relationship between these two events does seem plausible in the 
absence of any other likely confounding factor.  
 
Overdiagnosis occurs when an intervention results in detection of cancers that would not otherwise have 
become apparent during a patient’s lifetime. Whilst this is most commonly considered in the context of 
screening, other interventions to promote earlier diagnosis of cancer such as symptom awareness 
campaigns may also be subject to overdiagnosis. Overdiagnosed cases tend to be early stage, and may 
therefore reduce the proportion of patients diagnosed with late-stage disease by increasing the total 
number of diagnoses (and therefore the denominator for this proportion). A reduction in the absolute 
number of advanced cancers is therefore the preferred parameter for judging the true benefit of an 
intervention aimed at earlier diagnosis of cancer. Thus the demonstration of a 9.3% reduction in the 
number of patients diagnosed with stage III/IV lung cancer from 1,254 in the pre-campaign period 
(2008-2010) to 1,137 during the established campaign (2013-2015) is an important finding that would 
suggest such a beneficial effect of this intervention unrelated to overdiagnosis.  
 
The fact that annual lung cancer diagnoses returned to near baseline rates would also tend to suggest 
that overdiagnosis was minimal. Assuming that a sustained increase in CXR referral rates is necessary 
to maintain earlier diagnosis, an increase in the number of CXRs per cancer diagnosed would be 
anticipated, and was demonstrated in the data presented here. 
 
The shift towards earlier stage disease was accompanied by a reduction in the proportion of lung cancer 
cases diagnosed following emergency presentation to secondary care. Emergency presentation of lung 
cancer is recognised as a poor patient experience and is associated with worse outcomes which likely 
reflect case mix factors such as stage and performance status.7,8 The definitions used for route to 
diagnosis did not match those subsequently published by NCRAS and thus limits comparison with 
national data. For example, LTH commenced a direct to CT pathway during the study, which 
significantly reduced the number of formal 2-week-wait referrals and thus all outpatient referrals were 
considered as a single group in the data presented here. The reduction in the proportion of patients 
diagnosed with NSCLC not otherwise specified cases has been widely observed elsewhere in the UK,12 
and is driven by advances in systemic therapy requiring sub-classification of NSCLC where possible. 
Assessment of lung cancer treatment rates over the course of the study are limited by evolving 
oncological practice unrelated to the interventions described here. The introduction of SABR in Leeds 
in 2009 and the increased use of concurrent chemoradiation over this period may confound survival and 
mortality analysis in this study.  
 
A reduction in the number and percentage of lung cancer patients from the most deprived quintile was 
observed. Interestingly though, there was no difference in stage distribution between the five index of 
multiple deprivation (IMD) quintiles (data not shown) across the whole study period. Furthermore, an 
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increase in the proportion of patients diagnosed with early stage disease was observed in all IMD 
quintiles during the campaign (data not shown). Thus, if a causal link does exist between the awareness 
campaign, CXR rates and lung cancer stage distribution, this relationship appears to be independent of 
deprivation. There was no significant change in deprivation or age distribution in the population with 
the Leeds City Council boundary during the study (data not shown).  
 
An assessment of a six week UK nationwide lung cancer public awareness campaign in 2012 also 
showed an increase in the number of GP-referred CXRs (18·6% increase, p<0·001) and in the 
proportion of patients diagnosed with stage I NSCLC (3·1 percentage point increase, p<0.001) in a three 
month period (comprising the campaign and immediate aftermath) compared to earlier control 
periods.13 The larger increase in community-referrals for CXR (80·8%) and in Stage I disease (8·1 
percentage points) described here may relate to the more sustained nature of interventions in Leeds over 
several years and longer follow-up time. Considering national trends over longer time periods, a 
reduction in the proportion of lung cancer cases diagnosed following emergency presentation has been 
observed across England (39% in 2006, 34% in 2013).14 Furthermore, 1-year lung cancer survival has 
improved nationally since 2008, with a peak annual improvement of 2·2% per annum for patients 
diagnosed in 2010-2012.15 The cause of these trends is likely to be multifactorial, but may reflect 
alterations in treatment (increased lung cancer resection rates, introduction of new radiotherapy 
techniques and systemic treatments) as well as possible earlier diagnosis prompted by nationwide 
awareness campaigns. Comparisons with stage distribution of lung cancer nationally are limited by 
incomplete stage data, and previous recording of small cell lung cancer (SCLC) according to limited or 
extensive stage rather than using the TNM classification. Data from NLCA (personal communication 
Professor Richard Hubbard, Dr Aamir Khakwani) and NCRAS for 2011-2016 are shown in Table 7. 
The number of lung cancer cases diagnosed at stage I/II as a proportion of all those with a TNM (seventh 
edition) stage at LTH compared with national data from NLCA and NCRAS are shown in Figure 4. 
However, these comparisons should be made with caution, as these data may not truly reflect overall 
stage distribution due to bias relating to exclusion of SCLC and unstaged cases. The proportion of 
unstaged cases from 2011 NCRAS data is particularly high (28·2%), which may limit the robustness of 
this comparison but has been retained for completeness. The 2016 data for LTH were taken directly 
from the NLCA 2017 annual report,16 and have not been subject to individual case review as occurred 
for LTH data from 2008-2015. No statistical comparison has been made, but there appears to be a 
divergence between Leeds and national data from 2013 onwards.  
 
The US Prostate Lung Colorectal and Ovarian study (PLCO) demonstrated no mortality reduction and 
only a small stage-shift in lung cancer diagnoses (4·6 percentage point increase in stage I diagnoses) 
following yearly CXR screening for lung cancer.17 Whilst there are clear differences between PLCO 
and this study both in design (screening versus early symptomatic detection) and staging data (PLCO 
used TNM fifth edition with SCLC cases recorded separately), the larger stage-shift demonstrated here 
merits comment. The proportion of patients in Leeds diagnosed with stage I disease increased by 8·1 
percentage points from 17·0% to 25·1% following the early diagnosis campaign, but this is still less 
than the proportion of patients with stage I disease in the usual care (i.e. unscreened) arm of PLCO 
(27·1%). The possible beneficial effect of increased referral for CXR in our study may therefore reflect 
the more adverse stage distribution of lung cancer in our baseline state compared to the usual care arm 
of the PLCO study.  
 
Analysis of lung cancer survival over the course of the campaign is subject to biases (lead-time and 
overdiagnosis) and the confounding effects of evolving oncological therapy. Assessment of mortality 
avoids lead-time phenomenon and overdiagnosis, but is still confounded by changes in treatment 
unrelated to the campaign. Age-standardised mortality rates for lung cancer were significantly higher 
in Leeds than England and Wales prior to the campaign. These rates reduced in both areas over the 
course of the campaign, more strongly so in Leeds.  
 
The relationship between respiratory symptoms and subsequently diagnosed cancer has been recently 
studied. An analysis of a UK-based case-control study18 estimated a symptom lead time for lung cancer 
of only two to three months.19 The authors argue that expediting a diagnosis by this interval may not be 
sufficient to result in a stage-shift, and thus any stage-shift demonstrated in the context of a symptom 
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awareness campaign may instead reflect the incidental diagnosis of lung cancer in patients with 
symptoms of other causes. This maybe the mechanism for the stage-shift demonstrated here.  
 
The strengths of this study are the sustained and multifaceted nature of the early diagnosis campaign, 
and the comprehensive staging data including historical controls restaged according to a contemporary 
system to allow assessment of time trends. Furthermore, the very large increase in community-ordered 
CXRs over a 5-year period allows an unprecedented assessment of possible effects on increased use of 
CXR in response to respiratory symptoms on lung cancer characteristics and outcomes. There are 
several important weaknesses to this study. First, it took place in a single city, which limits the 
generalisability of the study results. Replication of these findings in other locations is needed to assess 
external validity. Second, there was no contemporary control population; similar nationwide early 
diagnosis campaigns over the period of our intervention preclude the use of other parts of England as 
uncontaminated control areas, and limitations of national data are discussed previously. Third, the study 
design means that no direct causal link can be drawn between the increase in rate of CXR referrals and 
any studied lung cancer parameter. Fourth, there are confounding factors such as evolving oncological 
practice which are likely to influence lung cancer outcomes. Finally, any survival effect demonstrated 
may simply reflect a lead-team phenomenon.  
 
In summary, this study demonstrates a large increase in community CXR referral rates in response to a 
public and health professional-facing lung cancer symptom awareness campaign. An increase in the 
proportion of lung cancer patients diagnosed with early stage disease, and importantly a reduction in 
the actual number of cases diagnosed with advanced disease have been observed. A causal link between 
these observations cannot be proven but appears plausible. Further analyses will include health 
economic evaluation of the interventions described and ongoing review to assess whether these changes 
result in a significant reduction in lung cancer-specific mortality in Leeds over coming years.  
 
Word count = 3,986  
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 Pre-campaign 
 
Early campaign Established campaign 
Year  
 
2008 2009 2010 2011 2012 2013 2014 2015 
GP requested CXRs 
 
17,673 18,804 20,251 26,764 33,959 29,570 34,606 33,531 
Self-request CXRs 
 
0 0 0 2516 1617 2519 1536 821 
Total community-
ordered CXRs 
17,673 18,804 20,251 29,280 35,576 32,089 36,142 34,352 
 
 
Table 1: Community-ordered chest X-ray rates at Leeds Teaching Hospitals from 2008-2015 
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 Pre-campaign 
 
Early campaign Established campaign 
Year of lung cancer 
diagnosis 
2008 2009 2010 2011 2012 2013 2014 2015 
Total lung cancer 
diagnoses 
577 576 578 608 649 574 589 608 
Sex 
 
Male· 
 
299  
(51·8) 
295  
(51·2) 
301  
(52·1) 
299 
 (49·2) 
330  
(50·8) 
295 
 (51·4) 
276  
(46·9) 
288 
(47·4) 
Female 
 
278  
(48·2) 
281  
(48·8) 
277  
(47·9) 
309 
(50·8) 
319 
(49·2) 
279  
(48·6) 
313 
(53·1) 
320 
(52·6) 
Linear trend: χ2(1)=4·01; p=0·05 
 
Age 
 
<55yrs 
 
43 
(7·5) 
36 
(6·3) 
28 
(4·8) 
36 
(5·9) 
40 
(6·2) 
33 
(5·7) 
39 
(6·6) 
32 
(5·3) 
55-59yrs 
 
26 
(4·5) 
38 
(6·6) 
31 
(5·4) 
35 
(5·8) 
37 
(5·7) 
43 
(7·5) 
35 
(5·9) 
32 
(5·3) 
60-64yrs 
 
53 
(9·2) 
72 
(12·5) 
71 
(12·3) 
60 
(9·9) 
56 
(8·6) 
66 
(11·5) 
56 
(9·5) 
70 
(11·5) 
65-69yrs 
 
90  
(15·6) 
93 
(16·1) 
66 
(11·4) 
94 
(15·5) 
87 
(13·4) 
95  
(16·6) 
80 
(13·6) 
116 
(19·1) 
70-74yrs 
 
106 
(18·4) 
92 
(16·0) 
116 
(20·1) 
109 
(17·9) 
123 
(19·0) 
89 
(15·5) 
109 
(18·5) 
95 
(15·6) 
75-79yrs 
 
108 
(18·7) 
96 
(16·7) 
112 
(19·4) 
114 
(18·8) 
130 
(20·0) 
98 
(17·1) 
107 
(18·2) 
110 
(18·1) 
≥80yrs 
 
151 
(26·2) 
149 
(25·9) 
154 
(26·6) 
160 
(26·3) 
176 
(27·1) 
150 
(26·1) 
163 
(27·7) 
153 
(25·2) 
Linear trend: χ2(1)=0.00; p=0.97 
 
Index of multiple deprivation 
 
IMD quintile 1  
(most deprived) 
253 
(43·8) 
237 
(41·1) 
232 
(40·1) 
232 
(38·2) 
230 
(35·4) 
215 
(37·5) 
217 
(36·8) 
224 
(36·8) 
IMD quintile 2 
 
115 
(19·9) 
121 
(21·0) 
110 
(19·0) 
145 
(23·8) 
142 
(21·9) 
131 
(22·8) 
134 
(22·8) 
124 
(20·4) 
IMD quintile 3 
 
57 
(9·9) 
84 
(14·6) 
74 
(12·8) 
73 
(12·0) 
97 
(14·9) 
70 
(12·2) 
82 
(13·9) 
96 
(15·8) 
IMD quintile 4 
 
103 
(17·9) 
86 
(14·9) 
93 
(16·1) 
109 
(17·9) 
123 
(19·0) 
94 
(16·4) 
88 
(14·9) 
117 
(19·2) 
IMD quintile 5  
(least deprived) 
43 
(7·5) 
38 
(6·6) 
45 
(7·8) 
45 
(7·4) 
55 
(8·5) 
60 
(10·5) 
63 
(10·7) 
45 
(7·4) 
IMD quintile 
unknown 
 
6 
(1·0) 
10 
(1·7) 
24 
(4·2) 
4 
(0·7) 
2 
(0·3) 
4 
(0·7) 
5 
(0·8) 
2 
(0·3) 
Linear trend: χ2(1)=9·6; p=0·002 (excluding IMD unknown) 
 
Performance status 
 
PS 0 
 
54 
(9·4) 
60 
(10·4) 
42 
(7·3) 
56 
(9·2) 
59 
(9·1) 
55 
(9·6) 
58 
(9·8) 
34 
(5·6) 
PS 1 
 
193 
(33·4) 
164 
(28·5) 
169 
(29·2) 
165 
(27·1) 
227 
(35·0) 
160 
(27·9) 
180 
(30·6) 
221 
(36·3) 
PS 2 
 
119 
(20·6) 
114 
(19·8) 
123 
(21·3) 
141 
(23·2) 
131 
(20·2) 
152 
(26·5) 
130 
(22·1) 
127 
(20·9) 
PS 3 
 
142 
(24·6) 
151 
(26·2) 
161 
(27·9) 
158 
(26·0) 
158 
(24·3) 
150 
(26·1) 
154 
(26·1) 
164 
(27·0) 
PS 4 
 
62 
(10·7) 
78 
(13·5) 
75 
(13·0) 
76 
(12·5) 
69 
(10·6) 
52 
(9·1) 
60 
(10·2) 
57 
(9·4) 
PS unknown 
 
7 
(1·2) 
9 
(1·6) 
8 
(1·4) 
12 
(2·0) 
5 
(0·8) 
5 
(0·9) 
7 
(1·2) 
5 
(0·8) 
Linear trend: χ2(1)=0·96; p=0·33 (excluding PS unknown) 
 
 
Table 2: Number, sex, age and quintile of deprivation for patients diagnosed with lung cancer at Leeds 
Teaching Hospitals 2008-2015.  
All data presented as number of cases with percentage of total in parentheses. Changes over the eight calendar 
years were assessed by Chi-square test with one degree of freedom. 
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 Pre-campaign 
 
Early campaign Established campaign 
Year of lung cancer 
diagnosis 
2008 2009 2010 2011 2012 2013 2014 2015 
Stage (TNM 7th edition) 
 
Stage I 
 
96 
(16·6) 
87 
(15·1) 
111 
(19·2) 
111 
(18·3) 
132 
(20·3) 
141 
(24·6) 
155 
(26·3) 
149 
(24·5) 
Stage II 
 
50 
(8·7) 
63 
(10·9) 
51 
(8·8) 
58 
(9·5) 
58 
(8·9) 
54 
(9·4) 
63 
(10·7) 
64 
(10·5) 
Stage III 
 
129 
(22·4) 
136 
(23·6) 
120 
(20·8) 
123 
(20·2) 
147 
(22·7) 
114 
(19·9) 
113 
(19·2) 
117 
(19·2) 
Stage IV 
 
295 
(51·1) 
284 
(49·3) 
290 
(50·2) 
307 
(50·5) 
309 
(47·6) 
264 
(46·0) 
256 
(43·5) 
273 
(44·9) 
Unknown stage 
 
7 
(1·2) 
6 
(1·0) 
6 
(1·0) 
9 
(1·5) 
3 
(0·5) 
1 
(0·2) 
2 
(0·3) 
5 
(0·8) 
Linear trend: χ2(1)=32·2; p<0·0001 (excluding stage unknown) 
 
Pathological subtype 
 
Adenocarcinoma 
 
117 
(20·3) 
91 
(15·8) 
128 
(22·1) 
122 
(20·1) 
182 
(28·0) 
198 
(34·5) 
181 
(30·7) 
179 
(29·4) 
Squamous Cell 
Carcinoma 
95 
(16·5) 
99 
(17·2) 
113 
(19·6) 
130 
(21·4) 
156 
(24·0) 
107 
(18·6) 
120 
(20·4) 
115 
(18·9) 
Non-Small Cell Lung 
Cancer NOS 
72 
(12·5) 
69 
(12·0) 
48 
(8·3) 
59 
(9·7) 
47 
(7·2) 
28 
(4·9) 
22 
(3·7) 
33 
(5·4) 
Large Cell Carcinoma 
 
26 
(4·5) 
43 
(7·5) 
26 
(4·5) 
21 
(3·5) 
13 
(2·0) 
12 
(2·1) 
13 
(2·2) 
13 
(2·1) 
Small Cell Carcinoma 
 
81 
(14·0) 
72 
(12·5) 
68 
(11·8) 
74 
(12·2) 
75 
(11·6) 
55 
(9·6) 
64 
(10·9) 
81 
(13·3) 
Carcinoid 
 
5 
(0·9) 
3 
(0·5) 
3 
(0·5) 
4 
(0·7) 
8 
(1·3) 
5 
(0·9) 
5 
(0·8) 
6 
(1·0) 
Unknown 
 
181 
(31·4) 
199 
(34·5) 
192 
(33·2) 
198 
(32·6) 
168 
(25·9) 
169 
(29·4) 
184 
(31·2) 
181 
(29·8) 
Linear trends (all analyses excluding unknown) 
Adenocarcinoma vs other types: χ2(1)=60·8; p<0·0001 
Squamous Cell Carcinoma vs other types: χ2(1)=0·9; p=0·33 
Non-Small Cell Lung Cancer NOS vs other types: χ2(1)=58·5; p<0·0001 
Large Cell Carcinoma vs other types: χ2(1)=30·5; p<0·0001 
Small Cell Carcinoma vs other types: χ2(1)=2·7; p=0·10 
Carcinoid vs other types: χ2(1)=0·57; p=0·45 
 
 
Table 3: Stage distribution and pathological subtype of lung cancer for patients presenting to Leeds 
Teaching Hospitals 2008-2015.  
All data presented as number of cases with percentage of total in parentheses. Changes over the eight calendar 
years were assessed by Chi-square test with one degree of freedom. 
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 Pre-campaign 
 
Early campaign Established campaign 
Year of lung cancer 
diagnosis 
 
2008 2009 2010 2011 2012 2013 2014 2015 
Route to diagnosis 
 
Emergency presentation 
 
214 
(37·1) 
201 
(34·9) 
208 
(36·0) 
192 
(31·6) 
183 
(28·2) 
162 
(28·2) 
171 
(29·0) 
177 
(29·1) 
Clinic referral (Fast-
track/Respiratory) 
213 
(36·9) 
204 
(35·4) 
218 
(37·7) 
252 
(41·4) 
310 
(47·8) 
272 
(47·4) 
298 
(50·6) 
306 
(50·3) 
Intra-hospital referral 
 
119 
(20·6) 
148 
(25·7) 
125 
(21·6) 
133 
(21·9) 
116 
(17·9) 
90 
(15·7) 
69 
(11·7) 
75 
(12·3) 
Other (nodule/ 
pneumonia) 
29 
(5·0) 
20 
(3·5) 
24 
(4·2) 
29 
(4·8) 
38 
(5·9) 
49 
(8·5) 
48 
(8·1) 
47 
(7·7) 
Unknown 
 
2 
(0·3) 
3 
(0·5) 
3 
(0·5) 
2 
(0·3) 
2 
(0·3) 
1 
(0·2) 
3 
(0·5) 
3 
(0·5) 
Linear trends (all analyses excluding unknown) 
Emergency presentation vs other routes: χ2(1)=20·1; p<0·001 
Clinic referral vs other routes: χ2(1)=60·0; p<0·001 
Intra-hospital referral vs other routes: χ2(1)=52·6; p<0·001 
Other (nodule/pneumonia) vs other routes: χ2(1)=19·8; p<0·001  
 
Treatment 
 
Surgical resection 
 
77 
(13·2) 
81 
(14·1) 
68 
(11·8) 
84 
(13·8) 
106 
(16·3) 
95 
(16·6) 
105 
(17·8) 
85 
(13·8) 
Radical oncological 
treatment 
21 
(3·6) 
41 
(7·1) 
67 
(11·6) 
71 
(11·7) 
92 
(14·2) 
92 
(16·0) 
86 
(14·6) 
102 
(16·8) 
Palliative oncology 
 
204 
(35·4) 
199 
(34·5) 
189 
(32·7) 
220 
(36·2) 
238 
(36·7) 
193 
(33·6) 
203 
(34·5) 
208 
(34·2) 
Best supportive care 
 
274 
(47·5) 
254 
(44·1) 
253 
(43·8) 
232 
(38·2) 
210 
(32·4) 
194 
(33·8) 
189 
(32·1) 
213 
(35·0) 
Other 
 
2 
(0·3) 
1 
(0·2) 
1 
(0·2) 
1 
(0·2) 
3 
(0·5) 
0 
(0·0) 
6 
(1·0) 
1 
(0·2) 
Linear trend radical treatment (surgical and radical oncology combined) vs others: χ2(1)=60·6; p<0·0001 
 
 
Table 4: Route to diagnosis and treatment of lung cancer for patients presenting to Leeds Teaching 
Hospitals 2008-2015.  
All data presented as number of cases with percentage of total in parentheses. Changes over the eight calendar 
years were assessed by Chi-square test with one degree of freedom. 
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 Pre-campaign 
 
Early campaign Established campaign 
Year of lung cancer 
diagnosis 
2008 
 
2009 2010 2011 2012 2013 2014 2015 
Median survival 
(days) 
 
163 191 155 196 242 211 276 240 
One year survival (%) 
 
175 
(30·3) 
199 
(34·5) 
176 
(30·4) 
214 
(35·2) 
256 
(39·4) 
225 
(39·2) 
250 
(42·4) 
238 
(39·1) 
Linear trend in one-year survival χ2(1)=26·0; p<0·0001 
 
 
Table 5: Lung cancer survival for patient presenting to Leeds Teaching Hospitals 2008-2015.  
One year survival data presented as number of cases with percentage of total in parentheses. Changes over the 
eight calendar years were assessed by Chi-square test with one degree of freedom. 
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Year  2008 
 
2009 2010 2011 2012 2013 2014 2015 2016 
Lung cancer deaths England & 
Wales 
30,326 30,018 29,977 30,148 30,273 30,437 30,868 30,520 30,570 
Lung cancer age-standardised 
mortality rate England & Wales 
per 100,000 population 
(95% CI) 
64·4 
(63·7-
65·1) 
62·8 
(62·1-
63·5) 
61·8 
(61·1-
62·5) 
61·3 
(60·6-
62·0) 
60·4 
(59·7-
61·0) 
59·7 
(59·0-
60·4) 
59·3 
(58·7-
60·0) 
57·8 
(57·1-
58·4) 
56·9 
(56·3-
57·6) 
Lung cancer deaths Leeds 
 
532 475 509 478 480 502 454 455 464 
Lung cancer age-standardised 
mortality rate Leeds per 
100,000 population 
(95% CI) 
92·7 
(84·8-
100·6) 
82·0 
(74·6-
89·4) 
86·8 
(79·2-
94·4) 
81·7 
(74·4-
89·1) 
80·8 
(73·5-
88·1) 
83·6 
(76·3-
91·0) 
75·0 
(68·1-
82·0) 
74·1 
(67·3-
81·0) 
75·0 
(68·1-
81·8) 
 
 
Table 6: The numbers of deaths where the underlying cause was lung cancer (ICD-10 C33-C34) and the 
corresponding age-standardised mortality rate per 100,000 population for England and Wales and the 
geographical area defined by the May 2013 boundaries of the three Leeds Clinical Commissioning Groups 
from 2008 to 2016 (Source: Office for National Statistics)11 
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Year of lung 
cancer diagnosis 
2008 2009 2010 2011 2012 2013 2014 2015 2016 
Leeds Teaching Hospitals 
 
Stage I+II 
 
146  
(25·3) 
150  
(26·0) 
162  
(28·0) 
169  
(27·8) 
190  
(29·3) 
195  
(34·0) 
218  
(37·0) 
213 
(35·0) 
230* 
(37·2) 
Stage III+IV 
 
424  
(73·5) 
420 
 (72·9) 
410 
 (70·9) 
430 
 (70·7) 
456  
(70·3) 
378  
(65·9) 
369  
(62·6) 
390 
(64·1) 
375* 
(60·6) 
Stage Unknown 
 
7  
(1·2) 
6  
(1·0) 
6  
(1·0) 
9 
 (1·5) 
3  
(0·5) 
1 
 (0·2) 
2  
(0·3) 
5 
(0·8) 
14* 
(2·3) 
Total 
 
577 
 (100·0) 
576 
 (100·0) 
578 
 (100·0) 
608  
(100·0) 
649  
(100·0) 
574 
 (100·0) 
589  
(100·0) 
608 
(100·0) 
619* 
(100·0) 
Proportion Stage 
I+II of those with 
TNM stage (%) 
25·.6 26·3 28·3 28·2 29·4 34·0 37·1 35·3 38·0* 
National Lung Cancer Audit 
 
Stage I+II 
 
N/A N/A N/A 5,998  
(19·0) 
7,065  
(21·4) 
7,137  
(22·0) 
7,071  
(23·5) 
9,460 
(24·7) 
10,165 
(26·0) 
Stage III+IV 
 
N/A N/A N/A 19,264 
(60·9) 
20,227 
(61·2) 
19,607 
(60·3) 
20,474 
(68·2) 
26,871 
(70·2) 
27,163 
(69·6) 
Limited stage 
Small Cell  
N/A N/A N/A 1,038  
(3·3) 
1,120  
(3·4) 
1,114  
(3·4) 
0  
(0·0) 
0 
(0·0) 
0 
(0·0) 
Extensive stage 
Small Cell  
N/A N/A N/A 2,481  
(7·8) 
2,424  
(7·3) 
2,413  
(7·4) 
0  
(0·0) 
0 
(0·0) 
0 
(0·0) 
Stage Unknown 
 
N/A N/A N/A 2,857  
(9·0) 
2,199  
(6·7) 
2,231  
(6·9) 
2,481  
(8·3) 
1,938 
(5·1) 
1,710 
(4·4) 
Total 
 
N/A N/A N/A 31,638 
(100·0) 
33,035 
(100·0) 
32,502 
(100·0) 
30,026 
(100·0) 
38,269 
(100·0) 
39,038 
(100·0) 
Proportion Stage 
I+II of those with 
TNM stage (%) 
N/A N/A N/A 23·7 25·9 26·7 25·7 26·0 27·2 
National Cancer Registration and Analysis Service 
 
Stage I+II 
 
N/A N/A N/A 5,057  
(14·1) 
7,560  
(20·3) 
7,591  
(20·3) 
8,574  
(22·6) 
9,068 
(24·1) 
N/A 
Stage III+IV 
 
N/A N/A N/A 20,687 
(57·7) 
25,045 
(67·2) 
24,458 
(65·4) 
25,382  
(67·0) 
25,734 
(68·4) 
N/A 
Stage Unknown 
 
N/A N/A N/A 10,113 
(28·2) 
4,647  
(12·5) 
5,363  
(14·3) 
3,912 
 (10·3) 
2,839 
(7·5) 
N/A 
Total 
 
N/A N/A N/A 35,857 
(100·0) 
37,252 
(100·0) 
37,412 
(100·0) 
37,868 
(100·0) 
37,641 
(100·0) 
N/A 
Proportion Stage 
I+II of those with 
TNM stage (%) 
N/A N/A N/A 19·6 23·2 23·7 25·3 26·1 N/A 
 
Table 7: Lung cancer stage distribution for patients first presenting to Leeds Teaching Hospitals, and all 
patients in England and Wales from the National Lung Cancer Audit, and National Cancer Registration 
and Analysis Service 2008-2016.  
Except where otherwise stated, data presented as number of cases with percentage of total in parentheses. N/A 
indicates data not available. *Leeds Teaching Hospitals 2016 data taken directly from the National Lung Cancer 
Audit (not presented elsewhere in this paper).16  
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Figure 1: Number of community-ordered chest X-rays in Leeds per month from 2008-2015. GP, 
general practitioner. 
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Figure 2: Flowchart of cases identified from National Lung Cancer Audit and National Cancer 
Registration and Analysis Service, and those excluded from analysis for various reasons. 
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Figure 3: Lung cancer age-standardised mortality rates for England and Wales and the geographical 
area defined by the May 2013 boundaries of the three Leeds Clinical Commissioning Groups from 2008 
to 2016. Source: Office for National Statistics. 
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Figure 4: Percentage of patients with stage I/II lung cancer as a percentage of all those with a TNM 
stage from Leeds Teaching Hospitals (LTH), the National Lung Cancer Audit (NLCA) and the National 
Cancer Registration and Analysis Service (NCRAS) from 2008 to 2016. Leeds Teaching Hospitals 2016 
data taken directly from the National Lung Cancer Audit (not presented elsewhere in this paper). 
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